2023 World Conference on Lung Cancer (Posters)-EP13.01. Patient-Specific Factors as Prognostic Biomarkers in Extensive Disease SCLC

EP13.01. Patient-Specific Factors as Prognostic Biomarkers in Extensive Disease SCLC - PDF(Slides)

Pdf Summary

This retrospective cohort study aimed to identify prognostic biomarkers in patients with extensive disease small cell lung cancer (SCLC) treated with chemo-immunotherapy. The study included 70 patients and measured patient-specific factors such as sex, Eastern Cooperative Oncology Group Performance Status (ECOG-PS), and hematological parameters like neutrophil-lymphocyte ratio (NLR) and lactate dehydrogenase (LDH) before treatment initiation.<br /><br />The results showed a significant difference in median overall survival (OS) between men and women, with women having a longer survival (15 months vs. 8 months). Women also had a significantly longer progression-free survival (PFS) compared to men (6 months vs. 4 months). ECOG-PS was found to be associated with a significant difference in OS, with better outcomes for patients with lower ECOG-PS scores (0 vs. 1 vs. 2). However, ECOG-PS did not show significant differences in PFS. Elevated baseline LDH values were associated with worse OS outcomes.<br /><br />Overall, these patient-specific biomarkers, including sex, ECOG-PS, and initial LDH values, were found to have prognostic significance in advanced SCLC patients treated with chemo-immunotherapy. Determining these biomarkers could help in predicting patient outcomes and tailoring treatment approaches for better management of SCLC.

Asset Subtitle

Romana Wass

Meta Tag

Speaker Romana Wass

Topic SCLC & Neuroendocrine Tumors: Biomarkers & Radiomics

Keywords

retrospective cohort study

prognostic biomarkers

extensive disease small cell lung cancer

chemo-immunotherapy

ECOG-PS

neutrophil-lymphocyte ratio

LDH

overall survival

progression-free survival

patient outcomes